McKesson (MCK) DIvidends Date & History

Key Takeaways

• McKesson Corporation (MCK) pays a quarterly dividend of $0.94 per share, reflecting a recent 14.6% increase from $0.82.
• The dividend yield is modest at roughly 0.4%, well below the average for healthcare dividend stocks.
• The company has raised its dividend for 17 consecutive years, with a five-year annualized growth rate of about 13.7%.
• The payout ratio is very low, near 10% of earnings and roughly 8% of cash flow, signaling ample room for continued increases.
• McKesson is best classified as a dividend growth stock rather than a high-yield or income-oriented holding.

Dividend Overview

McKesson Corporation, one of the world's largest pharmaceutical distributors, operates a conservative but steadily growing dividend program. The company pays its dividend on a quarterly schedule, with its most recent increase lifting the payment to $0.94 per share. On an annualized basis, this works out to approximately $3.76 per share and a dividend yield of roughly 0.4%.

That yield is notably low relative to the broader market and the healthcare sector, which averages closer to 2.5%. As a result, McKesson is not a high-yield stock. Instead, it fits the profile of a dividend growth stock: one that prioritizes consistent, above-average payout increases over time rather than maximizing current income. For investors, the appeal lies less in the immediate yield and more in the long-term compounding of a rapidly rising per-share dividend backed by a dominant, cash-generative distribution business.

Dividend History and Growth

McKesson has established a reliable track record of returning capital to shareholders. The company has increased its dividend for 17 consecutive years, a streak that places it among the more consistent dividend growers in the healthcare sector. The five-year annualized dividend growth rate stands near 13.7%, a pace well above the typical single-digit increases seen across the market.

The most recent hike, announced in July 2026, raised the quarterly dividend by 14.6%, from $0.82 to $0.94 per share. This followed a series of regular annual increases, with the quarterly payout climbing from $0.62 in early 2024 to $0.71 in 2025 and $0.82 in early 2026 before the latest step higher. The consistent cadence of increases reflects management's confidence in the stability of its cash flows and its commitment to a predictable, compounding distribution policy.

Dividend Sustainability and Payout Ratio

McKesson's dividend appears highly sustainable by conventional measures. The company pays out only about 10% of its earnings as dividends, and roughly 8% of its operating cash flow, based on trailing figures. These are exceptionally low payout ratios, leaving a substantial cushion of retained earnings and cash flow that can absorb earnings volatility while still supporting future increases.

The low payout ratio is underpinned by a resilient business model. As a core intermediary in the pharmaceutical supply chain, McKesson generates significant and relatively stable cash flow regardless of which specific drugs gain market share. This structural stability, combined with a modest debt burden relative to its size and earnings power, provides strong coverage for the current dividend. Even under a meaningful earnings downturn, the payout would remain comfortably funded, supporting the view that the dividend is secure and that further growth is likely over time.

Dividend Compared to Industry Peers

Within the pharmaceutical distribution space, McKesson competes primarily with CAH (Cardinal Health) and COR (Cencora, formerly AmerisourceBergen). Among these major distributors, McKesson generally carries the lowest dividend yield, typically in the low single digits, while peers offer somewhat higher current income.

What McKesson gives up in yield, it tends to make up for in dividend growth. Its roughly 13.7% five-year growth rate is among the fastest in the industry, and its payout ratio is near the bottom of its peer group. This positions McKesson as a growth-oriented alternative for investors who are willing to accept lower current income in exchange for faster compounding of their dividend over time. For yield-focused investors, however, other healthcare names may present more immediate income appeal.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool that helps traders and investors filter the market using technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs with customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener can also help identify dividend stocks, income-focused investments, trending stocks, and breakout candidates far more efficiently than manual screening. For investors seeking names with strong dividend growth profiles similar to McKesson, the AI Screener offers a fast, data-driven way to surface and compare opportunities across the market.

Is This Stock Attractive for Dividend Investors?

McKesson is best suited to dividend growth investors and long-term, total-return-focused investors rather than those seeking immediate income. With a yield near 0.4%, the stock does not serve the needs of income investors who depend on current payouts to meet expenses. Instead, its appeal lies in the combination of a low payout ratio, a 17-year growth streak, and a double-digit five-year growth rate, all of which suggest the dividend can continue compounding at an above-average pace.

Conservative investors may also appreciate the stability of McKesson's cash flows and the wide margin by which the dividend is covered. However, because a large share of the stock's total return has historically come from price appreciation rather than dividends, investors should view McKesson primarily as a growth-and-income hybrid tilted toward growth. As with any equity, dividend history is not a guarantee of future results, and investors should weigh the stock's valuation and growth outlook alongside its payout characteristics before making any decision.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations